The data are incrementally positive but not a stock-moving catalyst, the Phase 3 EMPEROR readout in Q3 2027 is the key binary event. Monitor for any regulatory updates or changes to the NDA timeline. The 4-year durability data de-risks the mechanism modestly but does not change the probability of success for the pivotal study.
BIIB drugs
BIIB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 4 $220.83entry
- T+1 · 2mo ago −3.77%α −3.22% · $212.50
- T+5 · 2mo ago −1.57%α −0.36% · $217.36
- T+20 · 6w ago +1.25%α +0.65% · $223.59
- T+50 · todayOpen
- T+60 · in 14d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Biogen (BIIB) and partner Stoke Therapeutics (STOK) presented positive 4-year open-label extension data for zorevunersen in Dravet syndrome at the European Epilepsy Congress, showing durable seizure reductions and cognitive/behavioral improvements. The Phase 3 EMPEROR study data readout is anticipated in Q3 2027, with a rolling NDA submission planned for H2 2027. This is a clinical update with no financial terms disclosed, and the stock-moving catalyst remains the Phase 3 results over a year away.
Key Facts
- 4-year OLE data showed 93% (75/81) of eligible patients continued treatment; 77% (58/75) remained at data cutoff
- Statistically significant improvements in cognition and behavior at 1, 2, 3, and 4 years vs OLE baseline
- Substantial reductions in generalized tonic-clonic and focal-to-bilateral tonic-clonic seizures through 3 years
- Quality of life improvements demonstrated through 28 months via EQ-VAS
- Phase 3 EMPEROR study (n=162 in primary analysis population) data readout expected Q3 2027
- Rolling NDA submission to FDA planned for H2 2027
- Zorevunersen generally well tolerated; >930 doses administered as of July 31, 2026
- Elevated CSF protein in ~94% of patients, 59% as treatment-emergent AE; no serious clinical manifestations or hydrocephalus
- Stoke retains US/Canada/Mexico rights; Biogen has rest-of-world commercialization rights
Financial Impact
No financial terms or deal values disclosed in this press release. The collaboration structure (Stoke retains North America, Biogen rest-of-world) was previously announced.
Risk Factors
- Phase 3 EMPEROR study may fail to replicate Phase 1/2a results
- Elevated CSF protein, while asymptomatic to date, could become a safety signal in larger/longer trials
- Competing Dravet syndrome therapies (e.g., fenfluramine, stiripentol, cannabidiol) may erode market opportunity
- Regulatory approval timeline could slip beyond H2 2027
- Commercialization depends on partnership execution between Stoke and Biogen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356336 |
Track record
34 reports on BIIB
10 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jul 13, 2026 report. 16 of 17 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 3/10 Entry $253.40 Now $251.65 −0.69% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $253.25 Now $251.65 −0.63% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $254.87 Now $251.65 −1.26% settles Feb 5
- Oct 28, 202619d ago Institutional Cluster Neutral 2/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $244.05 Now $251.65 +3.11% settles Jan 26
- Oct 19, 202628d ago Press Release Neutral 4/10 Entry $233.48 Now $251.65 +7.78% settles Jan 14
- Oct 12, 20265w ago ANALYST-UPGRADE Bullish 6/10 Entry $229.41 Now $251.65 +9.69% settles Jan 7
- Oct 2, 20266w ago Press Release Bullish 6/10 Entry $219.88 Now $251.65 +14.45% settles Dec 29
- Sep 17, 20268w ago Press Release Bullish 5/10 Entry $215.50 Now $251.65 +16.77% settles Dec 14
- Sep 3, 202610w ago Press Release Neutral 4/10 Viewing Entry $220.83 Now $251.65 +13.96% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers